title: New therapeutic approaches for treatment of tularaemia: a review.
abstract: Antibiotic treatment of tularaemia is based on a few drugs, including the fluoroquinolones (e.g., ciprofloxacin), the tetracyclines (e.g., doxycycline), and the aminoglycosides (streptomycin and gentamicin). Because no effective and safe vaccine is currently available, tularaemia prophylaxis following proven exposure to F. tularensis also relies on administration of antibiotics. A number of reasons make it necessary to search for new therapeutic alternatives: the potential toxicity of first-line drugs, especially in children and pregnant women; a high rate of treatment relapses and failures, especially for severe and/or suppurated forms of the disease; and the possible use of antibiotic-resistant strains in the context of a biological threat. This review presents novel therapeutic approaches that have been explored in recent years to improve tularaemia patients' management and prognosis. These new strategies have been evaluated in vitro, in axenic media and cell culture systems and/or in animal models. First, the activities of newly available antibiotic compounds were evaluated against F. tularensis, including tigecycline (a glycylcycline), ketolides (telithromycin and cethromycin), and fluoroquinolones (moxifloxacin, gatifloxacin, trovafloxacin and grepafloxacin). The liposome delivery of some antibiotics was evaluated. The effect of antimicrobial peptides against F. tularensis was also considered. Other drugs were evaluated for their ability to suppress the intracellular multiplication of F. tularensis. The effects of the modulation of the innate immune response (especially via TLR receptors) on the course of F. tularensis infection was characterized. Another approach was the administration of specific antibodies to induce passive resistance to F. tularensis infection. All of these studies highlight the need to develop new therapeutic strategies to improve the management of patients with tularaemia. Many possibilities exist, some unexplored. Moreover, it is likely that new therapeutic alternatives that are effective against this intracellular pathogen could be, at least partially, extrapolated to other human pathogens.
authors.affiliation: Laboratoire de Bactériologie, Institut de Biologie et de Pathologie, CHU de Grenoble Grenoble, France ; Université Joseph Fourier-Grenoble 1 Grenoble, France ; Laboratoire Adaptation et Pathogénie des Micro-Organismes, CNRS/UJF, UMR 5163 Grenoble, France.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Boisset
authors.affiliation: Laboratoire de Bactériologie, Institut de Biologie et de Pathologie, CHU de Grenoble Grenoble, France ; Université Joseph Fourier-Grenoble 1 Grenoble, France ; Laboratoire Adaptation et Pathogénie des Micro-Organismes, CNRS/UJF, UMR 5163 Grenoble, France.
authors.forename: Yvan
authors.initials: Y
authors.lastname: Caspar
authors.affiliation: Laboratoire de Bactériologie, Institut de Biologie et de Pathologie, CHU de Grenoble Grenoble, France ; Université Joseph Fourier-Grenoble 1 Grenoble, France ; Laboratoire Adaptation et Pathogénie des Micro-Organismes, CNRS/UJF, UMR 5163 Grenoble, France.
authors.forename: Vivien
authors.initials: V
authors.lastname: Sutera
authors.affiliation: Laboratoire de Bactériologie, Institut de Biologie et de Pathologie, CHU de Grenoble Grenoble, France ; Université Joseph Fourier-Grenoble 1 Grenoble, France ; Laboratoire Adaptation et Pathogénie des Micro-Organismes, CNRS/UJF, UMR 5163 Grenoble, France.
authors.forename: Max
authors.initials: M
authors.lastname: Maurin
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000379:methods*; D055808:Drug Discovery / Q000639:trends; D005604:Francisella tularensis / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D014406:Tularemia / Q000517:prevention & control* / Q000628:therapy*
chemical_list: D000900:Anti-Bacterial Agents
keywords: antibiotics; antibodies; immunotherapy; treatment; tularaemia
references.citation: Res Vet Sci. 2004 Jun;76(3):195-8
references.pmid: 15046952
references.citation: Clin Infect Dis. 2001 Aug 15;33(4):573-6
references.pmid: 11462198
references.citation: J Antimicrob Chemother. 2014 Jan;69(1):101-10
references.pmid: 23963236
references.citation: Iran Biomed J. 2012;16(3):156-61
references.pmid: 23023217
references.citation: Int J Antimicrob Agents. 2005 Oct;26(4):279-84
references.pmid: 16143497
references.citation: Scand J Infect Dis. 2002;34(5):327-30
references.pmid: 12069013
references.citation: J Immunol. 1999 Feb 15;162(4):2291-8
references.pmid: 9973506
references.citation: Cell Immunol. 2010;264(1):104-9
references.pmid: 20570250
references.citation: Clin Infect Dis. 1993 Dec;17(6):976-80
references.pmid: 8110955
references.citation: Semin Respir Infect. 1997 Mar;12(1):61-7
references.pmid: 9097380
references.citation: Ann N Y Acad Sci. 2007 Jun;1105:378-404
references.pmid: 17468229
references.citation: Jpn J Infect Dis. 2006 Aug;59(4):229-34
references.pmid: 16936340
references.citation: Virulence. 2013 Nov 15;4(8):859-70
references.pmid: 23959031
references.citation: J Antimicrob Chemother. 2010 Nov;65(11):2359-67
references.pmid: 20837574
references.citation: Medicine (Baltimore). 1985 Jul;64(4):251-69
references.pmid: 3892222
references.citation: Vaccine. 2012 Jul 13;30(33):4977-82
references.pmid: 22652404
references.citation: Antimicrob Agents Chemother. 2012 Feb;56(2):666-71
references.pmid: 22083489
references.citation: J Immunol. 2002 Oct 1;169(7):3883-91
references.pmid: 12244186
references.citation: Emerg Infect Dis. 2010 Feb;16(2):238-43
references.pmid: 20113553
references.citation: Vector Borne Zoonotic Dis. 2013 Mar;13(3):160-3
references.pmid: 23421891
references.citation: Antimicrob Agents Chemother. 2004 Dec;48(12):4513-9
references.pmid: 15561819
references.citation: Clin Microbiol Rev. 2002 Oct;15(4):631-46
references.pmid: 12364373
references.citation: Antimicrob Agents Chemother. 2013 May;57(5):2191-8
references.pmid: 23459474
references.citation: Nat Genet. 2005 Feb;37(2):153-9
references.pmid: 15640799
references.citation: J Antimicrob Chemother. 2013 Feb;68(2):370-3
references.pmid: 23065699
references.citation: Front Microbiol. 2011 Feb 16;2:26
references.pmid: 21687418
references.citation: Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):68-70
references.pmid: 1864276
references.citation: Clin Infect Dis. 1999 Oct;29(4):922-4
references.pmid: 10589911
references.citation: Int J Antimicrob Agents. 2006 May;27(5):439-43
references.pmid: 16621457
references.citation: J Immunol. 2008 Jun 1;180(11):7574-81
references.pmid: 18490759
references.citation: Arch Intern Med. 1987 Feb;147(2):265-8
references.pmid: 3813743
references.citation: Vaccine. 2008 Dec 9;26(52):6874-82
references.pmid: 18930100
references.citation: Immunol Lett. 2007 Oct 15;112(2):92-103
references.pmid: 17764754
references.citation: Antimicrob Agents Chemother. 1997 Jun;41(6):1288-92
references.pmid: 9174185
references.citation: Infection. 2009 Dec;37(6):514-21
references.pmid: 19826763
references.citation: Scand J Infect Dis. 2013 Sep;45(9):725-7
references.pmid: 23746340
references.citation: Antimicrob Agents Chemother. 2010 Sep;54(9):3922-6
references.pmid: 20625157
references.citation: J Antimicrob Chemother. 2000 Aug;46(2):287-90
references.pmid: 10933655
references.citation: J Antimicrob Chemother. 2011 Nov;66(11):2588-92
references.pmid: 21856791
references.citation: J Immunol. 2007 Apr 1;178(7):4538-47
references.pmid: 17372012
references.citation: Drug Deliv. 2015;22(5):581-9
references.pmid: 24313827
references.citation: Peptides. 2013 May;43:96-101
references.pmid: 23500517
references.citation: Microbes Infect. 2009 Jan;11(1):49-56
references.pmid: 18992838
references.citation: Immunol Rev. 2008 Oct;225:244-55
references.pmid: 18837786
references.citation: Clin Infect Dis. 2011 Nov;53(10):e133-41
references.pmid: 22002987
references.citation: Emerg Infect Dis. 2013 Jun;19(6):996-8
references.pmid: 23735285
references.citation: J Control Release. 2003 Oct 30;92(3):265-73
references.pmid: 14568408
references.citation: Clin Vaccine Immunol. 2013 Mar;20(3):319-27
references.pmid: 23283640
references.citation: Chin Med J (Engl). 2010 Jul;123(13):1727-30
references.pmid: 20819637
references.citation: J Antimicrob Chemother. 2005 Dec;56(6):1069-73
references.pmid: 16223941
references.citation: Clin Microbiol Infect. 2001 Mar;7(3):167-8
references.pmid: 11318818
references.citation: Ann N Y Acad Sci. 2007 Jun;1105:284-324
references.pmid: 17468235
references.citation: J Antimicrob Chemother. 2005 Sep;56(3):470-80
references.pmid: 16040625
references.citation: Antimicrob Agents Chemother. 2000 Dec;44(12):3428-31
references.pmid: 11083651
references.citation: J Antimicrob Chemother. 2012 Oct;67(10):2429-33
references.pmid: 22763567
references.citation: J Hyg Epidemiol Microbiol Immunol. 1980;24(1):84-91
references.pmid: 7190590
references.citation: Clin Infect Dis. 1994 Jul;19(1):42-7
references.pmid: 7948556
references.citation: PLoS Pathog. 2012;8(3):e1002587
references.pmid: 22438809
references.citation: APMIS. 1993 Jan;101(1):33-6
references.pmid: 8384458
references.citation: Clin Vaccine Immunol. 2009 Mar;16(3):414-22
references.pmid: 19176692
references.citation: J Immunol. 2007 Jul 1;179(1):532-9
references.pmid: 17579074
references.citation: Infect Immun. 2010 Apr;78(4):1700-10
references.pmid: 20123717
references.citation: J Immune Based Ther Vaccines. 2010 Feb 05;8(1):2
references.pmid: 20181102
references.citation: Blood. 1991 Sep 15;78(6):1420-7
references.pmid: 1884014
references.citation: Expert Opin Investig Drugs. 2008 Mar;17(3):387-400
references.pmid: 18321237
references.citation: PLoS One. 2011;6(10):e25333
references.pmid: 22031815
references.citation: Expert Rev Anti Infect Ther. 2008 Apr;6(2):231-40
references.pmid: 18380605
references.citation: APMIS. 2008 Jan;116(1):66-73
references.pmid: 18254782